Health

#SFHS2608602VNotice on Pharmaceutical Specialty Prices

🇫🇷France··Other·Medium Impact·View source ↗

AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.

🇬🇧 English

This notice sets the prices for specific pharmaceutical products made by ASCENDIS PHARMA FRANCE. It details the pricing for different dosages of YORVIPATH, an injectable solution. The prices are effective starting from the fifteenth day after being published in the Journal officiel.

AI-generated summary. May contain errors. Refer to official sources for legal decisions.

Key Changes

  • Introduction of fixed prices for YORVIPATH products
  • Specified dosages of injectable solutions
  • Prices become effective 15 days post-publication

Obligations

What this law requires

high

ASCENDIS PHARMA FRANCE must apply the fixed prices for YORVIPATH (palopegteriparatide) 168 mg/0.56 ml: PFHT €7,311.16 and PPTTC €7,598.22 per box of 2 pre-filled pens (CIP 34009 302 889 8 6)

ASCENDIS PHARMA FRANCE
operational
high

ASCENDIS PHARMA FRANCE must apply the fixed prices for YORVIPATH (palopegteriparatide) 294 mg/0.98 ml: PFHT €7,311.16 and PPTTC €7,598.22 per box of 2 pre-filled pens (CIP 34009 302 889 9 3)

ASCENDIS PHARMA FRANCE
operational
high

ASCENDIS PHARMA FRANCE must apply the fixed prices for YORVIPATH (palopegteriparatide) 420 mg/1.4 ml: PFHT €7,311.16 and PPTTC €7,598.22 per box of 2 pre-filled pens (CIP 34009 302 890 0 6)

ASCENDIS PHARMA FRANCE
operational
high

The specified pharmaceutical prices must become effective on the fifteenth day following publication in the Journal officiel de la République française

ASCENDIS PHARMA FRANCE
operational

Affected Parties

ASCENDIS PHARMA FRANCEHealthcare providers

Tags

pharmaceutical,pricing,France